【P4 Countdown 3-Week Agenda Launch】Biomarkers/Early screening/Prognosis/Drug Companion Diagnosis and other tumor forward-looking precision diagnosis and treatment dry goods issues are coming!

P4 China The 6th International Conference on Precision Oncology 2022 will be held in Beijing on November 25-26, 2022!

This year, the conference will focus on the three major sections of early tumor screening and early detection, prognosis/drug resistance monitoring/pathology, immunity/targeted drugs, and more than 60 academicians/regulators/clinicians/scientific research authoritative experts and KOLs from precision pharmaceutical companies/diagnostic companies will be invited to attend, and more than 1,000 industry elite representatives in the field of precision medicine will gather on the scene to share the new progress of forward-looking research and explore the new direction of tumor precision medicine technology development and transformation!

Click to view the official website of the forum: www.
bmapglobal.
com

[Double 11 group purchase offer surprise open! ] 】

Register P4 before November 11 to enjoy the buy 2 get 1 free surprise group purchase discount, 4 people and above participation discount welcome to contact: 177 2112 0767 (same as WeChat)

Scan the QR code below to enjoy the Double 11 special offer!

[The wonderful agenda of the conference is first released! ] 】

Main Forum: Regulatory Trends/Policy Interpretation/Industry Frontiers
▪ Current Status of Oncology Precision Medicine and the Latest Precision Drug Development Strategy (Quasi)
Qimin Zhan, Academician
▪ of Chinese Academy of Engineering
Li Jinming, the standardization of LDTs for tumor precision medicine, is the deputy director of the Clinical Laboratory Center and the director of the Clinical Molecular and Immunology Department of
▪ the National Health Commission The latest lung cancer early screening and early diagnosis and future precision medicine strategy
Li Weimin, Dean of West China Hospital/West China Clinical Medical College of Sichuan University Topic confirmation in Roche
diagnosis
▪ Requirements and Thoughts on Clinical Trial Technical Review Requirements and Thoughts
of Clinical Trials of Original Companion Diagnostic Reagents Xu Chao, reviewer and project manager of the Second Department of
▪ Clinical and Biostatistics of the Instrument Review Center of the State Food and Drug Administration
▪ High-end roundtable discussion: Rapids, the road to upgrading the tumor precision ecosystem How to cooperate between production, learning, research and medicine to
promote precision medicine
 Application and registration pain point analysis and LDT model exploration
 Domestic substitution
of raw materials/instruments/underlying technologies Supply chain construction and maintenance strategies
under the epidemic Moderator of Genetic Big Data Considerations and Challenges
: Yao Shukun, former vice president of China-Japan Friendship Hospital, Xu Chao, chairman of the Precision Medicine Committee of the Chinese Society of Bioengineering, reviewer and project manager of the Second Department of Clinical and Biostatistics of the Instrument Review Center of
the State Food and Drug Administration

Sub-forum A: Early Tumor Screening/Early Detection
▪ Xing
Jinliang, PI of the State Key Laboratory of Tumor Biology, Air Force Medical University, Chairman of
▪ the Tumor Marker Professional Committee of the Chinese Anti-Cancer Association Yan Linghua, chairman, CEO and
founder of Tongshu Genetics
▪ IDT methylation capture sequencing protocol
Wang Bingyin, IDT (Shanghai) Biotechnology Co.
, Ltd.
Application Manager
▪ topic confirmation Zhongzhenhe

▪ Research progress
of early screening of pan-cancer species based on MERCURY multi-omics liquid biopsy technology Wang Xiaonan, Co-founder, Director and CTO
▪ of Shihe Genomics
Zhang Zhihong, Chief Technology Officer
▪ of Ranshi Medical The discovery, application and cooperation
of whole cancer markers is Wenqiang, senior PI of the Institute of Biomedical Sciences, Fudan University, and a distinguished researcher
▪ of Fudan University Free DNA fragmentation patterns and their application
in the early diagnosis of pan-cancer species SUN Kun, Distinguished Researcher
▪ of Shenzhen Bay Laboratory Progress and clinical practice
of early tumor screening technology Jiang Yanfang, director of the Genetic Diagnosis Center of the First Hospital of Jilin University and the Forensic Identification Center of Laboratory Testing of the First Hospital of Jilin University, and the secretary-general of the Precision Medicine Committee of the
▪ Chinese Society of Bioengineering Discussion on
the Strategy of Combining Fecal DNA Testing for Bowel Cancer with Medical Testing Practice in China Zhang Lianglu, Chairman and General Manager
▪ of Wuhan Amieson Life Science and Technology Co.
, Ltd.
The development logic, transformation and application
of early tumor screening products in Xiaotian, Nova Health CMO
▪ Non-chromosomal circular DNA biomarker detection and significance of gastrointestinal tumors—
Xiao Fei, Director of Clinical Biological Sample Management Center, Beijing Hospital, Director of the Cell Department
▪, Institute of Geriatrics, Health Commission Application of
Automated Overall Solution in Oncology Precision Medicine, Marketing Director
▪ of Naonda Biotechnology Panel Discussion: Development
and Implementation of Prospective Tumor Screening Technology Pan-cancer/multi-cancer VS single cancer, small cancer Difficulties in multi-cancer screening "organ traceability"
 Better methylation strategy

 Difficulties such as performance/compliance of early screening products broke through
Jiang Yanfang, Director of the Genetic Diagnosis Center of the First Hospital of Jilin University and the Laboratory and Testing Judicial Identification Center of the First Hospital of Jilin University, Yu Xiaotian, Secretary-General
of the Precision Medicine Committee of the Chinese Society of Bioengineering, Ouyang Zhuojun, CMO
of Nova Health, General Manager of
▪ Tongze Hexin (Beijing) Pharmaceutical Technology Co.
, Ltd
.
Somatic mutation and clonal expansion of normal tissues in human body Fan Bai, Biomedical Frontier Innovation Center (BIOPIC), Peking University, Beijing Advanced Innovation Center for Future Genetic Diagnostics (ICG), School of Life Sciences/Full Professor Development of single-cell multi-omics technology and its application
in tumor diagnosis Cao Gang, Professor
▪, Huazhong
▪ Agricultural University Application of
glycoexosomes in early tumor screening LIN Changqing, Chairman and General Manager
▪ of Beijing Rejing Biotechnology Co.
, Ltd.
Research and Application
of Genetic Diagnosis in Precision Diagnosis and Treatment of Thyroid Cancer Jiang Yi, Senior Vice President and Director of Dean Diagnostics Research progress and clinical value
of
▪ methylation detection technology in gynecological tumor detection Liu Yuli, CMO of Beijing Origin Juhe Biotechnology Co.

▪ Clinical application
of multi-omics urine liquid biopsy technology in early screening of urological tumors, CTO of Beijing Oakin Biotechnology Co.
, Ltd

Forum B: Tumor Diagnosis/Prognosis/Drug Resistance Monitoring/Pathology
▪ Strategy and prospect
of precise diagnosis and treatment of colorectal cancer Wang Xishan, Director of Department of Colorectal Surgery, National Cancer Center/Cancer Hospital of Chinese Academy of
▪ Medical Sciences Guidelines and Data Quality Standards for Precision Genetic Testing and High-throughput Sequencing Technology for Tumors (Quasi)
HUANG Jie, Director of the Non-infectious Disease Diagnostic Reagent Department (TBD), Institute of In Vitro Diagnostic Reagent Control, Chinese People's Procuratorate Clinical Application and Future Development of MRD Dynamic Monitoring Zhang Xian, Chief Medical Officer of Shihe Genomics Group Several applications
of pathological images and tissue microorganisms in tumor prognosis assessment Yang Jialiang, Deputy General Manager/Chief Information Officer
▪ of
Yuancode Gene Technology (Beijing) Co.
,
▪ Ltd
▪ More sensitive hematologic tumor MRD monitoring breakthrough and clinical application evaluation and suggestions
Chen Wenming, Director of
▪ Hematology, Beijing Chaoyang Hospital, Capital Medical University Clinical opinions
on MRD monitoring and precision diagnosis and treatment of bowel cancer based on tumor-informed customized panel, Professor and Chief Physician of Peking University Cancer Hospital, President of Peking University Shougang Hospital (TBD)
▪ Clinical opinions on MRD monitoring and tumor precision diagnosis and treatment of customized panel (proposed)
Cui Jiuwei, Deputy Director
▪ of Cancer Center, First Hospital of Jilin University The latest progress and future direction
of clinical implementation of precision diagnosis/medical treatment Yao Shukun, former vice president of China-Japan Friendship Hospital,
▪ Zhang Bo, Standardized Detection
of MSI Tumor Pathology, Professor/Chief Physician
▪, Department of Pathology, Peking University Health Science Center/Third Hospital From tissue to blood, a full range of tumor immune markers clinical transformation research
Jiao Lei, CEO
▪ of Bainuo Panorama Biotechnology (Beijing) Co.
, Ltd.
Hepatobiliary tumor targeting and companion diagnosis in immunotherapy
Zhao Jingmin, Director of the Department of Pathology, Fifth Medical Center, PLA General Hospital, Deputy Director
▪ of the All-Army Institute of Infectious Diseases Panel Discussion: Challenges and breakthroughs
in the clinical implementation of precision diagnosis and treatment of tumors Precision detection and drug development/medication
 Marker Research/Companion Diagnosis and Clinical Suggestions
Moderator: Dong Zengjun, Zhang Bo, Vice Chairman of the Precision Medicine Committee of the Chinese Society of Bioengineering and Investment Partner
of Kunpeng Medical, Cui Qiang, Professor/Chief Physician of the Department of Pathology/Third Hospital, Peking University Health Science Center, Director of Diagnosis, CStone Medical Affairs Department Zhong Dingrong, Director of the Department of
▪
▪ Pathology, China-Japan Friendship Hospital, talks about early cancer screening
from a pathological perspective Technical progress and problems of liquid biopsy and AI in tumor screening and monitoring
Chen Shifu, Founder/Chief Technology Officer
▪ of Hypros Zhong Sheng, a multi-omics-based differential diagnosis platform
for benign and malignant lung nodules, co-founder
▪ of Shenzhen Taylor's Biotechnology Co.
, Ltd.
Spatial genomic imaging helps to understand the molecular mechanism in the precise diagnosis and treatment of tumors
Juntao Gao is an associate researcher at the Beijing National Research Center for Information Science and Technology (BNRist) at Tsinghua University

Sub-forum C: Tumor Immunology/Targeted Drugs
▪ Suggestions on the Direction and Strategy of Lymphoma Targeting and Immunotherapy Drug R&D Song Yuqin, Deputy Director, Department of Lymphoma, Peking
▪ University Cancer Hospital The impact of human genetic resources management regulations on
tumor drug development and the new trend
of human legacy managementExpert of China Biotechnology Development Center (TBD).

▪ Application of flow cytometry in the whole life cycle of ADC drug development Yang Chengmao, application expert
▪ of BIDI Medical Products Application and exploration
of microtumor PTC in the field of
tumor precision medicine Yin Shenyi, Chief Technology Officer
▪ of CStone Life NTRK inhibitor-lalotinib China R&D Wang Yukun, Bayer China R&D
Center/ Head of Cancer Translational Medicine, Bayer China Precision development of next-generation ROS1 inhibitors and exploration of biomarkers and companion diagnostics
, Medical Director of
▪ Baoyuan Biomedical Technology (Hangzhou) Co.
, Ltd.
Liu Xiaoqiao, medical director
▪ of Keytruda TMB-H pan-cancer biomarker research and companion diagnostic development
, Associate Director
▪ of Bioinformatics and Biomarker Research, Merck R&D (China) Co.
, Ltd.
Panel Discussion: How to Further Accelerate the Development of Differentiated Oncology Precision Drugs?
 Biomarker discovery and translation
 Translational research
 Companion diagnostic strategies
 Emerging Therapeutics and Precision Development
Zhirong Shen, Vice President of BeiGene and Global Head of
Translational Research and Translational Medicine, Gefei Zeng, Li Fugen, Head of Bioinformatics and Biomarker Research of Merck R&D (China) Co.
, Ltd.
, Guo Baohong, Senior Vice President of Haihe Drug Translational Medicine, Yi Li, Executive Medical Director of Corning Jereh, Pan Guohua, researcher of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, and CEO of



Huaxia Yingtai (Beijing) Biotechnology Co.
, Ltd
▪ Interpretation and Consideration
of Technical Guidelines for the Application of Biomarkers in the Clinical R&D of Antitumor Drugs Expert of Drug Review Center of the State Food and Drug Administration (TBD)
▪ Yan Guangmei, a companion diagnostic dual marker system
for new oncolytic virus M1, is a professor at Sun Yat-sen University, chairman and chief scientist
▪ of Guangzhou Weilite Pharmaceutical Technology Co.
, Ltd Latest clinical progress in
KRAS-G12C targeted drug mechanism and precision development Li Jing, Executive Director of
▪ Translational Medicine and Biomarkers of Zai Lab Topic Confirmation Zhongyue Microgene
▪ Topic Confirmation Zhongbaio

Zhihui
▪ DS8201-ADC Translational Medicine and Biomarker Research and Development
Qinmei Ji, Head of
▪ Daiichi Sankyo Translational Medicine LAG-3: Emerging Biomarkers
in the Immunotherapy Era Yongzi Li, Senior Director
▪, Medical Operations Strategy, Hematology and Biomarkers at Bristol-Myers Squibb EGFR/ MET bispecific antibody precision therapy biomarker exploration (proposed)
Zhou Longen, head of
▪ Asia Pacific tumor translational research at Johnson & Johnson Pharmaceuticals Immune Microenvironment Characteristics in Multiple Myeloma Progression from Transcriptome Profiling
Li Wenjin, Head of Hematology and Oncology, Roche China Biomarker R&D Department Congcong
Zhang, Head of Biomarker Department of
▪ Yingpai Pharmaceutical

*The above updates are as of October 15, and the final agenda is subject to the scene! Real-time guest lineup and agenda information welcome to contact the organizing committee: 177 2112 0767 (same as WeChat)

【Special Thanks】

There is only one last sponsorship seat left, and the investment channel will be officially closed this Friday! Book as soon as possible! For details, please contact: 177 2112 0767 (same as WeChat)

【Free participation for medical staff】

The medical community forwards the designated push to the circle of friends (retained for at least 24 hours) or 2 or more hospital groups/alumni groups/precision medicine/tumor treatment and other related communities, with the words "All medical workers can participate for free!" 1000+ industry representatives participated, come and join! ", you can take a screenshot to contact the conference affairs team to get a free registration link, please consult for details: 177 2112 0767 (same as WeChat)

*Note: [Medical group] refers to medical personnel who hold valid medical practice certificates recognized by the state nationwide (relevant practice certificates of licensed physicians, licensed assistant physicians, licensed pharmacists, nurses (teachers), medical technicians and other health technicians)

For details of sponsorship/participation/speech, please contact the organizing committee: Tel: 177 2112 0767 (same as WeChat)
Email: p4china@bmapglobal.
com
Website:
www.
bmapglobal.
com/p4china2022

Media cooperation contact:
Zhao Junwen | Shanghai Business Map Information Consulting Co.
, Ltd
Jane Zhao
Tel:+86 136 6556 4971Official
Website: www.
bmapglobal.
com